Faruqi and Faruqui, LLP Logo
Share this page

Esperion Therapeutics, Inc. (ESPR)

NASDAQ:ESPR

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Esperion Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (NASDAQ:ESPR) of the July 6, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Esperion stock or options between February 22, 2017 and May 1, 2018 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the Eastern District of Michigan on behalf of all those who purchased Esperion securities between February 22, 2017 and May 1, 2018 (the “Class Period”). The case, Bailey v. Esperion Therapeutics, Inc. et al, No. 2:18-cv-11438 was filed on May 7, 2018 and has been assigned to District Judge Robert H. Cleland.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to appropriately disclose the safety risks associated with Esperion's cholesterol-lowering medication, bempedoic acid.

Specifically, on May 2, 2018, Esperion announced results from its second pivotal Phase 3 study for bempedoic acid.  Esperion reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were thirteen deaths in the treatment group compared to only two in the control group.

After the announcement, Esperion’s share price fell from $70.50 per share on May 1, 2018 to a closing price of $45.75 on May 2, 2018—a $24.75 or a 35.1% drop.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Esperion Therapeutics, Inc. (ESPR)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 05/08/2018

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.